Edwards Lifesciences Corp (EW) Stock Analysis and Metrics

Edwards Lifesciences

NYSE: EW

$82.63 ▼ -1.19 (-1.42%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap55.28 Bn

P/E2,354.76

P/S8.77

Div. Yield0.00

Total Debt (Qtr)598.50 Mn

Revenue Growth (1y) (Qtr)16.70

Add ratio to table…

About

Edwards Lifesciences Corporation is a global medical technology company that focuses on structural heart disease. The firm develops manufactures and markets therapies for aortic mitral tricuspid and pulmonary valve conditions. Its portfolio includes transcatheter and surgical solutions that aim to restore normal valve function and improve patient outcomes. Founded over six decades ago the company builds on a legacy of innovation begun by its founder Miles Lowell Edwards. Edwards Lifesciences continues to invest in research and clinical evidence to expand the use of its products across different risk groups and geographies.

Revenue is generated primarily from the sale of three product groups. The Transcatheter Aortic Valve Replacement group includes the SAPIEN family of valves and contributed about seventy four percent of net sales in 2025. The Transcatheter Mitral and Tricuspid Therapies group comprises repair and replacement systems such as PASCAL EVOQUE and SAPIEN M3 and accounted for roughly nine percent of net sales in 2025. The Surgical Structural Heart group consists of tissue valves and related devices and represented approximately seventeen percent of net sales in 2025. The company also earns revenue from associated services and support activities that complement its device sales.

The company reports its operations in three segments: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, and Surgical Structural Heart.

• Transcatheter Aortic Valve Replacement includes the SAPIEN family of transcatheter heart valves. These valves are delivered via catheter while the heart continues to beat and are used to treat severe aortic stenosis. The segment also covers related systems such as the Alterra system for pulmonary valve replacement in congenital heart disease.

• Transcatheter Mitral and Tricuspid Therapies comprises the PASCAL repair system the EVOQUE replacement system and the SAPIEN M3 replacement system. These technologies address mitral and tricuspid regurgitation through leaflet approximation or valve replacement and are approved in major markets including the United States Europe and Japan.

• Surgical Structural Heart focuses on surgical tissue valves and related conduits. Products include the INSPIRIS RESILIA aortic valve the KONECT RESILIA valved conduit and the MITRIS RESILIA mitral valve. The segment benefits from the RESILIA tissue technology which aims to improve durability and reduce calcification.

Edwards Lifesciences holds a leading position in the structural heart market. The company is frequently cited as a top competitor in transcatheter aortic valve replacement alongside Medtronic and Abbott. In transcatheter mitral and tricuspid therapies Edwards faces competition primarily from Abbott while many other firms pursue early stage projects. In the surgical heart valve arena Edwards contends with Medtronic and Abbott as well. Competitive advantages stem from a deep body of clinical evidence a reputation for product reliability and a global commercial infrastructure that supports rapid adoption of new technologies. The firm’s focus on generating real world data and expanding indications helps to maintain its market share and to drive guideline changes.

The company sells its products to hospitals health systems and cardiac care centers worldwide. Its customers include interventional cardiologists cardiac surgeons physicians and hospital administrators who make purchasing decisions for valve therapies. Edwards also works with group purchasing organizations and government agencies that negotiate contracts for medical devices. While the filing does not disclose individual customer names the base consists of a diverse mix of public and private healthcare providers across North America Europe Asia and other regions.

Investment Thesis

▲ Bull case

Edwards Lifesciences is positioned to capitalize on a structural shift in the structural heart market driven by the convergence of long-term clinical evidence and evolving treatment guidelines that favor earlier intervention, particularly for asymptomatic and moderate aortic stenosis patients, which represents a vast untapped patient population beyond the current severe AS focus. The company's SAPIEN platform, reinforced by the ten-year Partner 2 and seven-year Partner 3 data demonstrating exceptional durability and safety, provides a differentiated foundation for expanding into earlier treatment paradigms, with the upcoming PROGRESS trial results on moderate AS expected to validate a significant expansion of the addressable market. This is further amplified by the European guideline changes reducing the TAVR age recommendation from 75 to 70 and endorsing proactive disease management regardless of symptoms, which, while not yet fully reflected in U.S. coverage, creates a durable growth tailwind as healthcare systems globally adopt these evidence-based protocols, increasing procedural volumes and shifting the standard of care toward earlier, more frequent intervention.
The transcatheter mitral and tricuspid therapies (TMTT) portfolio is emerging as a multi-year growth engine with significant upside potential, driven by the recent FDA approval of SAPIEN M3, the scaling of EVOQUE supported by strong TRISCEND II two-year data showing mortality benefits, and the impending launch of next-generation PASCAL for tricuspid and mitral patients in Q4 2026, which together address a large, underserved patient population with limited therapeutic options. Management highlighted that TMTT sales exceeded $550 million in 2025 and are on track to achieve the $2 billion revenue target by 2030, but the market may be underestimating the acceleration potential from the tricuspid-specific indications, particularly as EVOQUE demonstrates real-world safety and efficacy in the STS/ACC TVT Registry with over 1,000 patients, and the upcoming U.S. approval of PASCAL for tricuspid repair will create a first-mover advantage in a rapidly growing segment where competitors lack comparable technology. This vertical expansion within structural heart, combined with the company's proven high-value support model, positions TMTT to contribute disproportionately to top-line growth as adoption scales globally.
Edwards Lifesciences' capital allocation strategy and balance sheet strength provide a significant, underappreciated cushion for sustained value creation, with approximately $3 billion in cash and cash equivalents and $2 billion remaining under share repurchase authorization as of December 2025, enabling opportunistic buybacks even amid strategic investments in innovation and capacity expansion. The company's decision to terminate the GennaValve acquisition, while initially perceived as a setback, has freed up capital and operational focus, allowing for redirected investment toward higher-return opportunities in TAVR and TMTT, as evidenced by the increased confidence in 2026 EPS guidance of $2.90 to $3.05 despite higher-than-expected tax rates and patient access spending in Q4 2025. Furthermore, the anticipated appointment of Doretta Mistras as CFO, with her deep healthcare investment banking background at Goldman Sachs and Citigroup, signals enhanced financial discipline and strategic capital deployment capabilities that could optimize returns on invested capital and support long-term margin expansion beyond the current 150 basis point guidance for 2026.

Edwards Lifesciences is positioned to capitalize on a structural shift in the structural heart market driven by the convergence of long-term clinical evidence and evolving treatment guidelines that favor earlier intervention, particularly for asymptomatic and moderate aortic stenosis patients, which represents a vast untapped patient population beyond the current severe AS focus. The company's SAPIEN platform, reinforced by the ten-year Partner 2 and seven-year Partner 3 data demonstrating exceptional durability and safety, provides a differentiated foundation for expanding into earlier treatment paradigms, with the upcoming PROGRESS trial results on moderate AS expected to validate a significant expansion of the addressable market. This is further amplified by the European guideline changes reducing the TAVR age recommendation from 75 to 70 and endorsing proactive disease management regardless of symptoms, which, while not yet fully reflected in U.S. coverage, creates a durable growth tailwind as healthcare systems globally adopt these evidence-based protocols, increasing procedural volumes and shifting the standard of care toward earlier, more frequent intervention.
The transcatheter mitral and tricuspid therapies (TMTT) portfolio is emerging as a multi-year growth engine with significant upside potential, driven by the recent FDA approval of SAPIEN M3, the scaling of EVOQUE supported by strong TRISCEND II two-year data showing mortality benefits, and the impending launch of next-generation PASCAL for tricuspid and mitral patients in Q4 2026, which together address a large, underserved patient population with limited therapeutic options. Management highlighted that TMTT sales exceeded $550 million in 2025 and are on track to achieve the $2 billion revenue target by 2030, but the market may be underestimating the acceleration potential from the tricuspid-specific indications, particularly as EVOQUE demonstrates real-world safety and efficacy in the STS/ACC TVT Registry with over 1,000 patients, and the upcoming U.S. approval of PASCAL for tricuspid repair will create a first-mover advantage in a rapidly growing segment where competitors lack comparable technology. This vertical expansion within structural heart, combined with the company's proven high-value support model, positions TMTT to contribute disproportionately to top-line growth as adoption scales globally.
Edwards Lifesciences' capital allocation strategy and balance sheet strength provide a significant, underappreciated cushion for sustained value creation, with approximately $3 billion in cash and cash equivalents and $2 billion remaining under share repurchase authorization as of December 2025, enabling opportunistic buybacks even amid strategic investments in innovation and capacity expansion. The company's decision to terminate the GennaValve acquisition, while initially perceived as a setback, has freed up capital and operational focus, allowing for redirected investment toward higher-return opportunities in TAVR and TMTT, as evidenced by the increased confidence in 2026 EPS guidance of $2.90 to $3.05 despite higher-than-expected tax rates and patient access spending in Q4 2025. Furthermore, the anticipated appointment of Doretta Mistras as CFO, with her deep healthcare investment banking background at Goldman Sachs and Citigroup, signals enhanced financial discipline and strategic capital deployment capabilities that could optimize returns on invested capital and support long-term margin expansion beyond the current 150 basis point guidance for 2026.

▼ Bear case

Edwards Lifesciences faces significant near-term growth headwinds from lapping exceptionally strong comparable periods in 2025, particularly in the second half of 2026, where the lapping of the Partner 3 seven-year and Partner 2 ten-year data announcements from October 2025 will create a difficult year-over-year comparison that could obscure underlying organic growth, despite management's confidence in mid-to-high single-digit TAVR growth beyond 2026. The company's own guidance acknowledges that first-half 2026 growth will be stronger than the second half due to tougher comps, and with Q1 2026 already showing 11.0% constant currency TAVR growth, sustaining this pace through Q3 and Q4 will require continuous new catalysts, yet the pipeline beyond next-generation PASCAL and EVOQUE scaling lacks near-term, high-impact approvals, making the business vulnerable to growth deceleration if guideline adoption or NCD revisions delay further than anticipated.
The company's increased SG&A spending, which rose approximately $112 million year-over-year in Q4 2025 to fund patient access initiatives like the American Heart Association partnership and early TAVR education, represents a persistent margin pressure that may not fully moderate as planned in 2026, especially given the long-term nature of these investments in disease awareness and guideline implementation, which could keep SG&A as a percentage of sales elevated above historical levels and offset gross profit margin stability from manufacturing efficiencies. While management frames this as strategic and temporary, the scale of the increase—bringing SG&A to 38% of sales in Q4 2025 from 35% in the prior year—suggests a structural shift in cost base that may not fully reverse, particularly if the Heart Valve Initiative and asymptomatic TAVR education programs require sustained field force expansion and marketing spend, thereby constraining operating margin expansion despite favorable R&D trends.
Regulatory and reimbursement risks remain materially underappreciated, particularly regarding the U.S. National Coverage Determination (NCD) for TAVR, which management acknowledges may have a negligible impact in 2026 but could face delays or unfavorable revisions beyond the expected Q4 timeline due to ongoing debates over care team requirements and procedural complexity, as noted in the Q&A where public comments showed support for expanded indication but concern over implementation specifics. Furthermore, the scrapping of Edwards' anti-copycat policy (UPIP) following EU antitrust scrutiny, while resolving the immediate investigation, introduces competitive risks as rivals like Meril may now pursue legal challenges more freely in key European markets, potentially eroding the company's share gains from the Boston Scientific exit and increasing pricing or legal defense costs in a region that contributed 11.9% constant currency TAVR growth in Q4 2025, undermining the stability of its international growth engine.

Edwards Lifesciences faces significant near-term growth headwinds from lapping exceptionally strong comparable periods in 2025, particularly in the second half of 2026, where the lapping of the Partner 3 seven-year and Partner 2 ten-year data announcements from October 2025 will create a difficult year-over-year comparison that could obscure underlying organic growth, despite management's confidence in mid-to-high single-digit TAVR growth beyond 2026. The company's own guidance acknowledges that first-half 2026 growth will be stronger than the second half due to tougher comps, and with Q1 2026 already showing 11.0% constant currency TAVR growth, sustaining this pace through Q3 and Q4 will require continuous new catalysts, yet the pipeline beyond next-generation PASCAL and EVOQUE scaling lacks near-term, high-impact approvals, making the business vulnerable to growth deceleration if guideline adoption or NCD revisions delay further than anticipated.
The company's increased SG&A spending, which rose approximately $112 million year-over-year in Q4 2025 to fund patient access initiatives like the American Heart Association partnership and early TAVR education, represents a persistent margin pressure that may not fully moderate as planned in 2026, especially given the long-term nature of these investments in disease awareness and guideline implementation, which could keep SG&A as a percentage of sales elevated above historical levels and offset gross profit margin stability from manufacturing efficiencies. While management frames this as strategic and temporary, the scale of the increase—bringing SG&A to 38% of sales in Q4 2025 from 35% in the prior year—suggests a structural shift in cost base that may not fully reverse, particularly if the Heart Valve Initiative and asymptomatic TAVR education programs require sustained field force expansion and marketing spend, thereby constraining operating margin expansion despite favorable R&D trends.
Regulatory and reimbursement risks remain materially underappreciated, particularly regarding the U.S. National Coverage Determination (NCD) for TAVR, which management acknowledges may have a negligible impact in 2026 but could face delays or unfavorable revisions beyond the expected Q4 timeline due to ongoing debates over care team requirements and procedural complexity, as noted in the Q&A where public comments showed support for expanded indication but concern over implementation specifics. Furthermore, the scrapping of Edwards' anti-copycat policy (UPIP) following EU antitrust scrutiny, while resolving the immediate investigation, introduces competitive risks as rivals like Meril may now pursue legal challenges more freely in key European markets, potentially eroding the company's share gains from the Boston Scientific exit and increasing pricing or legal defense costs in a region that contributed 11.9% constant currency TAVR growth in Q4 2025, undermining the stability of its international growth engine.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password